The pooled HRs of cumulative meta-analysis ranged from 1.19(95%CI: 1.04-1.37) to 1.30 (95%CI: 1.08-1.55) for OS since 2012, demonstrating that performance of EGFR expression for prognosis in GC patients was stable and reliable. The gene discussed is EGFR; the disease is gastric cancer.